Only a few companies that trade as American Depositary Shares earn S&P's 'buy' rating.
The drug company is a defensive, income generator with added potential for capital gains.
The Swiss pharmaceutical has several very strong potential oncology drugs, most of which could be commercially successful.
The US approval of Stribild is a big plus for the company's AIDS treatment franchise.
With antibodies produced from mouse and human components, this biotech is advancing drug research.
An analyst says the weight-loss drug Qsymia can't live up to investors' expectations.
Shares of the world's largest drugmaker wobble from negative news on the company's Alzheimer's drug.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Fed may start tapering in just a few months. Here are a few of the likely winners and losers.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Even those who don't like to shop are probably hitting the stores this month. Here's what to be on the lookout for and here's what to avoid.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.